Basic Periactin Information

• INN (International Nonproprietary Name): Cyproheptadine
• Brand Names Available In Canada (English): Periactin is the globally recognized brand, but cyproheptadine is marketed under numerous other names and with country-specific packaging including Periactin (Australia, India, UK), Ciplactin (India), Ciproheptadina (Latin America, Spain), Cyproheptadine (USA generics), Cyheptine/Cyllermin (Thailand), and various national brands.
• ATC Code: R06AX02
• Forms & Dosages: Tablets 4 mg (common brand: Periactin, Ciplactin); Syrup 2 mg/5 mL (available in some US/EU generics).
• Manufacturers In Canada (English): Not specified
• Registration Status In Canada (English): Not specified — clinicians and pharmacists should check the Health Canada Drug Product Database and confirm DINs before prescribing or dispensing.
• OTC / Rx Classification: Internationally variable — Periactin is OTC in countries such as Australia and India, and prescription-only in the USA and EU. Local Canadian status should be confirmed via the Drug Product Database.

Major 2022–2025 Canadian & Global Studies

What does recent research actually show about periactin?

High-quality, large Canadian randomized controlled trials specifically on cyproheptadine from 2022–2025 are limited.

Internationally, the literature since 2022 is mostly small randomized trials and observational cohorts focusing on off-label uses such as appetite stimulation in paediatrics and oncology cachexia, plus niche uses like migraine prophylaxis.

Systematic reviews up to 2024 note a sparse contemporary RCT evidence base and reliance on older studies when estimating efficacy for many indications.

Main Outcomes

Which benefits are consistently reported?

Across studies, a consistent signal appears for modest appetite stimulation and short-term weight gain in children and frail adults when cyproheptadine is used for that purpose.

Results for chronic migraine prevention are variable, with benefit magnitude often small-to-moderate and study heterogeneity high.

Overall effect sizes tend to be modest; clinicians should set realistic expectations for appetite or weight gain responses.

Safety Observations

What safety signals arose in recent surveillance?

Pharmacovigilance reports from 2022–2025 highlighted sedation, anticholinergic adverse effects, and an increased fall risk in older adults taking cyproheptadine.

Regulatory listings such as Australia’s AUST R 62384 and active generic markets in the USA reflect continued availability but differing legal classifications between jurisdictions.

When counselling patients, mention that sedation and anticholinergic effects are the most commonly reported concerns in recent cohorts.

Layman’s Explanation

How does Periactin work in plain language?

Periactin (cyproheptadine) is a first-generation antihistamine that blocks histamine H1 receptors to reduce allergy symptoms like itching and runny nose.

It also affects serotonin and muscarinic receptors, which explains why some people experience increased appetite and drowsiness.

Scientific Breakdown

What’s happening at the receptor level?

Cyproheptadine has a multi-receptor profile: it is an H1 antagonist with notable 5‑HT2 (serotonin) antagonism and anticholinergic activity.

This combined action accounts for both the antihistamine benefits and the appetite-stimulating and sedative effects seen clinically.

Receptor-Level Detail

H1 blockade reduces pruritus, rhinorrhoea, and urticaria.

5‑HT2 antagonism is implicated in increased appetite and weight gain, useful in cachexia or failure-to-thrive contexts.

Anticholinergic activity and CNS penetration cause sedation, dry mouth, and potential urinary retention.

ATC code R06AX02 confirms its classification as an “other systemic antihistamine.”

Extra caution is advised in elderly patients and those with glaucoma or prostatic hypertrophy because of anticholinergic risks.

Health Canada Approvals (DIN-Based)

Can patients expect a Health Canada label for periactin?

Periactin is registered in some countries but the Canadian market presence is not explicitly detailed in the provided product data.

Clinicians and pharmacists should confirm any cyproheptadine product’s listing in the Health Canada Drug Product Database and verify DINs before prescribing or dispensing.

Legal classification varies internationally: Rx in the USA and EU, OTC in Australia and India.

Notable Off-Label Trends In Canadian Practice

How do Canadian prescribers use it off-label?

Observed off-label uses in Canadian practice and specialist literature include appetite stimulation for paediatric failure-to-thrive, adult cachexia, chronic migraine prophylaxis, and refractory pruritus.

Off‑label prescribing should include informed consent and documentation, particularly for children and pregnant or breastfeeding patients.

Community and hospital pharmacies will check DINs and provincial formulary listings (for example ODB, BC PharmaCare, RAMQ) and may require special authorizations for coverage.

General Dosing Per Health Canada Monographs

What dose is commonly used?

Adult dosing commonly used globally is 4 mg (one tablet) three times daily.

Paediatric dosing for children aged two years and older is often 2 mg (half a tablet) two to three times daily.

Infants under two years are generally not recommended to receive cyproheptadine.

Condition-Specific Dosing Adjustments

How are doses adjusted by indication and patient group?

For allergic reactions, short-term dosing such as 4 mg three times daily is typical with regular reassessment.

For appetite stimulation, clinicians commonly use 2–4 mg up to three times daily and reassess response after two to six weeks.

For migraine prophylaxis (off-label), specialist-directed dosing often goes up to 4 mg three times daily with slow titration and monitoring.

Older adults and patients with hepatic or renal impairment should start at a lower dose and be monitored for CNS and anticholinergic effects.

In overdose, expect CNS depression or excitation and anticholinergic signs; seek emergency care and provide supportive management.

Contraindications (Canadian Advisories)

Who should not take periactin?

Absolute contraindications include a known hypersensitivity to cyproheptadine or product excipients, newborns and premature infants, acute asthmatic attack, angle‑closure glaucoma, bladder neck obstruction, and recent MAOI use (within 14 days).

Use in pregnancy and lactation requires careful risk/benefit assessment.

Adverse Effects (Post-Market Reports)

What side effects should patients expect?

Common side effects include drowsiness, dry mouth, dizziness, increased appetite or weight gain, headache, and nausea.

Moderate to serious reactions reported post‑market include confusion—especially in elderly patients—urinary retention, visual disturbances, paradoxical excitation in children, and falls related to sedation.

Counselling points include avoidance of driving and machinery until response is known, and avoiding alcohol and other CNS depressants.

Food Interactions Common In Canadian Diet

Are there food interactions to watch for?

Alcohol and other sedating substances such as cannabis potentiate CNS depression and are relevant given Canadian consumption patterns.

No major grapefruit interaction is documented with cyproheptadine, though high‑fat meals may alter absorption of some formulations.

Drug Combinations Flagged By Health Canada

Which drug interactions matter most?

Concurrent MAOI use is contraindicated.

Additive CNS depression can occur with opioids, benzodiazepines, other antihistamines, and sedative antidepressants.

Coadministration with other anticholinergic drugs increases anticholinergic burden and risk of cognitive impairment, constipation, and urinary retention.

Because cyproheptadine has serotonergic antagonism, clinical effects may be modified when used with serotonergic agents; consult a pharmacist for polypharmacy risk, particularly in older adults.

Canadian Survey Data

What do patients report in Canada?

Specific, large-scale Canadian surveys are limited, but small clinic audits suggest that many patients using cyproheptadine off‑label for appetite report mixed satisfaction.

Patients often notice increased appetite and short-term weight gains but report sedation and dislike of daytime drowsiness.

Forum & Community Pharmacy Trends

What questions do pharmacists hear most often?

Community pharmacists report frequent questions about sedation, driving safety, and using Periactin as an appetite stimulant for children and seniors.

Online forums echo praise for appetite effects and complaints about daytime sleepiness and dry mouth.

Pharmacists note brand requests for Periactin are less common than searches for generics labelled cyproheptadine.

Practical implication: pharmacists should document counselling, screen for polypharmacy, and check provincial formularies before dispensing.

National Pharmacy Chains

How easy is it to find cyproheptadine in the big chains?

In Canada, patients typically obtain cyproheptadine via prescription and major chains such as Shoppers, Rexall, Jean Coutu, and London Drugs dispense based on DINs.

Brand Periactin may not be routinely stocked and pharmacies will often substitute generics when available.

Pharmacists check DINs, bilingual labelling requirements, and provincial coverage before dispensing.

Online Pharmacy Availability & Provincial Restrictions

Can Canadians order Periactin online?

Licensed Canadian online pharmacies may supply cyproheptadine with a valid prescription; cross‑border importation rules apply and Health Canada discourages uncontrolled imports.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare, and RAMQ may not list routine coverage for off‑label uses and special authorizations are often required.

In our online pharmacy, periactin is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

Why do prices and access differ between Canada and other countries?

Periactin and cyproheptadine variants are OTC in Australia and India but prescription-only in the US and EU, which affects availability and pricing.

US generics may be available in bottles or syrup and can be cheaper, but cross‑border purchasing carries regulatory and safety risks.

Comparison Of DIN-Approved Alternatives

What are safer allergy alternatives on most Canadian formularies?

• Loratadine (Claritin) — second-generation, non-sedating.
• Cetirizine (Zyrtec) — second-generation, low sedation for many patients.
• Fexofenadine (Allegra) — non-sedating, good for daytime allergy control.

Pros And Cons Checklist

How to choose between Periactin and alternatives?

Periactin (Cyproheptadine): Pros — appetite stimulation and multi-receptor action useful in refractory cases; Cons — sedation, anticholinergic burden, increased fall risk in elderly, variable availability, off‑label use for appetite.

Second-Generation Antihistamines: Pros — non‑sedating, favourable safety for allergy relief; Cons — no appetite stimulation and less utility for cachexia or migraine prophylaxis.

Choice should be indication-driven: use second‑generation options for straightforward allergic rhinitis and consider cyproheptadine only for targeted appetite or specialist‑directed uses.

Health Canada Approval Process

How does cyproheptadine get licensed in Canada?

Health Canada requires a Drug Identification Number (DIN) for marketed products, and manufacturers submit evidence for safety, efficacy, and labelling for review.

Clinicians and pharmacists should verify a product’s DIN and NOC status in the Drug Product Database before use.

DIN And Bilingual Labelling Rules

What packaging rules apply?

Prescription products sold in Canada must meet bilingual (English/French) labelling requirements and include DIN, lot number, expiry, storage instructions, and meet Good Manufacturing Practice standards.

Provincial drug plans use DINs to adjudicate reimbursement and special authorization pathways apply for off‑label prescribing.

Consolidated FAQ

Is Periactin (cyproheptadine) available in Canada without a prescription?

Typically no; availability varies and a DIN is required — check the Health Canada Drug Product Database and local pharmacies for status.

Can I use Periactin to help my child gain weight?

Off‑label use occurs, but it requires paediatric dosing, informed risk counselling about sedation, and clinical monitoring under physician supervision.

Will Periactin make me sleepy the next day?

Daytime drowsiness is common; avoid driving or operating machinery until you know your response and consider dosing in the evening to reduce daytime sedation.

Is it covered by provincial drug plans?

Often not routinely — check ODB, BC PharmaCare, and RAMQ; special authorizations may be necessary for off‑label uses.

Can I mix with alcohol or cannabis?

No — mixing increases additive CNS depression and raises the risk of falls and impairment.

Visual Guide Suggestions For Canadian Audiences

What graphics would help patients and prescribers?

Suggested infographics include a dosage flowchart showing adult versus paediatric starting doses and when to stop, a provincial coverage map flagging ODB, BC PharmaCare, and RAMQ, a risk/benefit matrix comparing appetite gain versus sedation by age group, and a purchase channels diagram showing in‑store chains versus licensed online pharmacies and cross‑border risks.

Design notes should include bilingual label samples, a storage icon for "store under 25°C", and warning icons for MAOI contraindications and avoiding alcohol.

Canadian Household Storage Guidelines

How should patients store Periactin at home?

Store tablets and syrup below 25°C and protect from moisture and light.

Keep medication in the original packaging with child‑resistant lids where applicable.

Dispose of expired medication through provincial medication return programs rather than household waste.

Cold-Chain Storage Where Applicable

Does Periactin need refrigeration?

No cold‑chain is required for standard tablet or syrup forms.

When shipping to remote or northern areas in Canada, avoid freezing during winter transit and package to prevent temperature extremes.

Pharmacies shipping medications must follow Canada Post and provincial handling guidelines and protect patient privacy.

Advice From Canadian Pharmacists

What checks should be done before dispensing?

Verify the DIN, the indication, patient age, pregnancy and lactation status, liver and renal function, and concurrent medications including MAOIs and CNS depressants.

Counsel on sedation risk and dose timing, document off‑label counselling, and establish a follow‑up plan.

For appetite trials, a 2–6 week follow‑up to assess benefit and side effects is recommended.

Provincial Health Authority Guidance

How should institutions approach cyproheptadine?

Align prescribing with provincial formularies and special authorization pathways such as ODB exceptional access.

In long‑term care, include fall‑risk assessments and deprescribing protocols to minimise anticholinergic burden in older adults.

When treating children for growth or appetite concerns, liaise with paediatric specialists where possible.

Concluding Practical Notes

Who should consider periactin and how should it be used?

Consider cyproheptadine for short‑term allergic relief when other options fail, for specialist‑directed appetite stimulation, or for niche uses under close supervision.

Always balance modest expected benefits against the well‑documented sedation and anticholinergic risks, particularly in older adults and patients on multiple CNS medications.

Delivery Across Canada (English)

Key Takeaways For Patients

What should someone considering Periactin remember?

Periactin (cyproheptadine) can help with itching and short‑term appetite stimulation, but modern RCT evidence is limited and benefits for some off‑label uses are modest.

Expect drowsiness and anticholinergic effects; elderly patients face higher risks of confusion and falls.

Always check with a prescriber or pharmacist about interactions, especially MAOIs and CNS depressants.

When To Call Your Pharmacist Or Doctor

Which symptoms need urgent attention?

Seek medical help for sudden confusion, severe urinary retention, visual disturbances, marked agitation or sedation, or signs of allergic reaction to the product.

If appetite goals are not met after a monitored 2–6 week trial, reassess the plan with a clinician.

References And Where To Check Product Details

Where can clinicians verify product licences and DINs?

Use the Health Canada Drug Product Database to confirm DINs, NOC status, and bilingual labelling requirements for any cyproheptadine product intended for Canadian use.

Final Practical Counselling Points

Summarized patient counselling checklist for pharmacists:

1. Confirm indication and verify DIN or product registration.
2. Screen for MAOI use, other CNS depressants, and anticholinergic medication burden.
3. Advise on sedation risk and recommend dosing at night if appropriate.
4. Set a 2–6 week follow‑up for appetite trials and document off‑label counselling.
5. Encourage safe storage below 25°C and proper disposal of expired medication.